Angiex’s IND application for AGX101 cleared by FDA
November 3, 2023Medical Communications AGX101, Angiex, FDA, Oncology
Angiex has announced that the US Food and Drug Administration has cleared its Investigational New Drug (IND) application for AGX101, …
FDA approves Phathom Pharmaceuticals’ Voquezna for erosive GERD
November 3, 2023Medical Communications Erosive GERD, FDA, Gastrointestinal tract, Phathom Pharmaceuticals, Voquezna
Phathom Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) tablets 10mg and 20mg, …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap
November 2, 2023Business Services AbbVie, Aldeyra Therapeutics, Opthalmology, reproxalap
Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement for the license to develop, …
ViroCell and GOSH gain MHRA manufacturing approval
November 1, 2023Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors
ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …
AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development
November 1, 2023Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine
AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …
Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment
October 31, 2023Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial
Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
October 30, 2023Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment
October 27, 2023Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
October 26, 2023Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
Eisai shares new data for Leqembi for Alzheimer’s treatment
October 26, 2023Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
FDA approves Servier Pharmaceuticals’ new MDS therapy
October 25, 2023Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes
The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …
GSK shares new data for RSV vaccine Arexvy
October 25, 2023Research and Development Arexvy, GSK, Immunology, RSV, Vaccine
GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …
AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA
October 24, 2023Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA
AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …
Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics
October 24, 2023Business Services Kurma Partners, Pharmacy, Samsung BioLogics
Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …
Roche announces acquisition of Telavant
October 23, 2023Business Services Gastrointestinal tract, Roche, Telavant
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
Latest content
FibroFind appoints Lee Borthwick as CEO
